Our results provide a strong rationale for clinical investigation of EphA2 inhibitor or its downstream inhibitor in patients having ESCC with PT fusions, which might also be useful in other types of cancers exhibiting PT fusions, besides ESCC. The gene discussed is EPHA2; the disease is esophageal squamous cell carcinoma.